BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia
BioXcel Therapeutics Achieved alignment with the FDA on sNDA package to expand the IGALMI label for the At-Home…